Basic HTML Version
95
SCIENTIFIC REPORT 2012
Title:
Randomized, double-blind, phase III study comparing the use of TAS-102 more
supportive care versus placebo plus supportive care in patients with colorectal cancer
metastatic resistant to conventional chemotherapies.
District Attorney:
Taiho Pharma USA, Inc.
Principal Investigator:
Carles Pericay Pajaume.
Title:
Open, randomized, phase III, cisplatin and 5 fluorouracil clinical trial with or without
panitumumab, in patients with advanced esophageal squamous cell carcinoma (CCHS)
the metastatic, not resectable.
District Attorney:
AIO-Studien-gGmbh.
Principal Investigator:
Carles Pericay Pajaume.
Title:
Retrospective observational study for the independent validation of a gene profile
predictive response to preoperative treatment with chemotherapy and radiotherapy in
rectal adenocarcinoma.
District Attorney:
GEMCAD.
Principal Investigator:
Carles Pericay Pajaume.
Title:
Open, multicenter, single-arm clinical trial to evaluate safety and
health-related quality of life of aflibercept in patients with colorectal cancer
metastatic (CCRm) previously treated with an oxaliplatin-containing regimen.
District Attorney:
Sanofi-Aventis SA
Principal Investigator:
Aleydis Pisa Gatell.
Title:
Clinical trial evaluating a non - pharmacological intervention (
comprehensive care or PAI) versus standard palliative chemotherapy treatment plus PAI in
patients with advanced cancer who have already received at least one first line of treatment
chemotherapeutic that has failed.
District Attorney:
Sant Pau Hospital Research Institute Foundation.
Principal Investigator:
Eugeni Saigí Grau.
Title:
Observational, prospective and multicenter study on the incidence of nausea and vomiting
with moderately emetogenic chemotherapy regimens.
District Attorney:
Merck Sharp & Dohme de España SA
Principal Investigator:
Eugeni Saigí Grau.